Arvinas (ARVN) Cash from Investing Activities (2017 - 2026)
Arvinas (ARVN) posted quarterly Cash from Investing Activities of $13.7 million for Q1 2026, down 80.29% year-over-year from $69.5 million in Q1 2025, and down 90.6% quarter-over-quarter from $145.8 million in Q4 2025.
Analysis
Arvinas (ARVN) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Arvinas' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at $13.7 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 80.29% year-over-year to $13.7 million; the TTM figure through Mar 2026 stood at $351.8 million (up 51.64% YoY), while the FY2025 annual figure was $407.6 million, up 1074.64% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $13.7 million, down from $145.8 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $145.8 million in Q4 2025, with the low at -$127.8 million in Q1 2024.
- The 5-year median for Cash from Investing Activities is $63.5 million (2025), against an average of $53.1 million.
- Peak annual rise in Cash from Investing Activities reached 1511.63% in 2023, while the deepest fall reached 376.8% in 2023.
- Arvinas' Cash from Investing Activities stood at $19.4 million in 2022, then sank by 376.8% to -$53.7 million in 2023, then jumped by 284.17% to $98.9 million in 2024, then soared by 47.42% to $145.8 million in 2025, then slumped by 90.6% to $13.7 million in 2026.
- Business Quant data shows ARVN's Cash from Investing Activities at $13.7 million in Q1 2026, $145.8 million in Q4 2025, and $63.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.37 Bn | 130.52 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.18 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.33 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.92 Bn | 52.78 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.48 Bn | 32.17 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.38 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Arvinas | 609.77 Mn | 41.87 Mn | - | 54.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 54.90 Mn |
| Mar 31, 2026 | 13.70 Mn |
| Dec 31, 2025 | 145.80 Mn |
| Sep 30, 2025 | 63.50 Mn |
| Jun 30, 2025 | 128.80 Mn |
| Mar 31, 2025 | 69.50 Mn |
| Dec 31, 2024 | 98.90 Mn |
| Sep 30, 2024 | 50.50 Mn |
| Jun 30, 2024 | 13.10 Mn |
| Mar 31, 2024 | -127.80 Mn |
| Dec 31, 2023 | -53.70 Mn |
| Sep 30, 2023 | 70.00 Mn |
| Jun 30, 2023 | 48.60 Mn |
| Mar 31, 2023 | 138.60 Mn |
| Dec 31, 2022 | 19.40 Mn |
| Sep 30, 2022 | 105.80 Mn |
| Jun 30, 2022 | 109.00 Mn |
| Mar 31, 2022 | 8.60 Mn |
| Dec 31, 2021 | -115.60 Mn |
| Sep 30, 2021 | -741.10 Mn |